Skip to main content

Table 2 Patient demographics after propensity score matching (fully adjusted model)

From: The impact of a heart failure management protocol based on a hospital-community pharmacist collaboration

 

Overall cohort (n = 46)

Intervention group (n = 23)

Control group (n = 23)

p

Age (years, mean ± SD)

80.2 ± 13.1

80.4 ± 11.8

80.0 ± 14.7

0.965

Male, n (%)

22 (47.8)

11 (47.8)

11 (47.8)

1.000

Living alone, n (%)

6 (13.0)

5 (21.7)

1 (4.3)

0.187

Medical history, n (%)

    

 Diabetes mellitus

12 (26.1)

7 (30.4)

5 (21.7)

0.738

 Previous HF admission

20 (43.5)

10 (43.5)

10 (43.5)

1.000

 Ischemic heart disease

20 (43.5)

11 (47.8)

9 (39.1)

0.767

 Artral fibrillation

34 (73.9)

16 (69.6)

18 (78.3)

0.738

 Previous CABG

4 (8.7)

3 (13.0)

1 (4.3)

0.608

 Previous PCI

14 (30.4)

8 (34.8)

6 (26.1)

0.749

Physical examination

    

 Systolic blood pressure (mmHg, mean ± SD)

113.3 ± 18.0

113.9 ± 18.5

112.6 ± 17.9

0.852

 Diastolic blood pressure (mmHg, mean ± SD)

66.2 ± 12.4

65.6 ± 11.6

66.7 ± 13.3

0.869

 Body mass index (kg/m2), n (%)

21.4 ± 4.1

21.0 ± 3.2

21.9 ± 4.9

0.852

 LVEF

49.5 ± 14.8

49.7 ± 13.2

49.3 ± 16.6

0.921

 LVEF < 50, n (%)

21 (45.7)

11 (47.8)

10 (43.5)

1.000

 Albumin (g/dL, mean ± SD)

3.2 ± 0.4

3.2 ± 0.4

3.3 ± 0.4

0.300

 Creatinine (mg/dL, mean ± SD )

1.36 ± 0.59

1.32 ± 0.60

1.40 ± 0.59

0.391

 Blood urea nitrogen (mg/dL, mean ± SD)

31.0 ± 14.4

29.1 ± 12.7

32.8 ± 16.1

0.538

 eGFR (mL/min/1.73m2, mean ± SD)

40.7 ± 17.9

42.7 ± 19.9

38.8 ± 15.8

0.645

 Hemoglobin (g/dL, mean ± SD)

12.0 ± 2.0

11.7 ± 1.8

12.3 ± 2.3

0.495

 Creatinine clearance (mL/min, mean ± SD)

35.7 ± 23.7

35.6 ± 20.5

35.9 ± 27.0

0.637

 NT-proBNP (pg/mL), median (IQR)

2809 (1596–5131)

3165 (1704–6078)

2428 (1322–3907)

0.307

Medication, n (%)

    

 Aspirin

8 (17.4)

3 (13.0)

5 (21.7)

0.699

 OACs

26 (56.5)

13 (56.5)

13 (56.5)

1.000

 Beta-blocker

37 (80.4)

18 (78.3)

19 (82.6)

1.000

 ACEi/ARB/ARNI

31 (67.4)

17 (73.9)

14 (60.9)

0.530

 MRA

23 (50.0)

14 (60.9)

9 (39.1)

0.238

 SGLT2i

18 (39.1)

6 (26.1)

12 (52.2)

0.130

 Loop diuretics

38 (82.6)

18 (78.3)

20 (87.0)

0.699

  1. We adjusted for 12 baseline covariates that were considered as factors that affected the current intervention, heart failure readmission, N-terminal pro-B-type natriuretic peptide level (pg/mL), and left ventricular ejection fraction (%)
  2. SD, standard deviation; HF, heart failure; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; IQR, interquartile range; LVEF, left ventricle ejection Fraction; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro brain natriuretic peptide; OACs, oral anticoagulants; ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor neprilysn inhibitors; MRA, mineralocorticoid receptor antagonists; SGLT2i, sodium-glucose cotransport-2 inhibitor
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us